BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28540896)

  • 1. Postrenal transplant malignancy: Incidence, risk factors, and prognosis.
    Elserwy NA; Lotfy EE; Fouda MA; Mahmoud MI; Donia AF; Mashaly ME; Abbas MH; Abuelmagd MM; Abouelenein RK; Ismail MI; Bakr MA
    Saudi J Kidney Dis Transpl; 2017; 28(3):579-588. PubMed ID: 28540896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De Novo Malignant Neoplasms in Renal Transplant Patients.
    Yılmaz Akçay E; Tepeoğlu M; Özdemir BH; Deniz E; Börcek P; Haberal M
    Exp Clin Transplant; 2016 Nov; 14(Suppl 3):100-105. PubMed ID: 27805524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
    Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience.
    Zilinska Z; Sersenova M; Chrastina M; Breza J; Bena L; Baltesova T; Jurcina A; Roland R; Lackova E; Cellar M; Laca L; Dedinska I
    Neoplasma; 2017; 64(2):311-317. PubMed ID: 28052685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaposi's sarcoma after renal transplantation.
    Abbaszadeh S; Taheri S
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):775-8. PubMed ID: 19736472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
    Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
    Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of the Original Kidney Disease and Its Effect on the Outcome of Kidney Transplant in the Urology-Nephrology Center Mansoura University.
    Mashaly ME; Ismail MI; Lotfy EE; Donia AF; Wafa IW; Foda MA; Denewar AA; Abbas MH; Shokeir AA
    Exp Clin Transplant; 2016 Apr; 14(2):157-65. PubMed ID: 26788876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation.
    Pendón-Ruiz de Mier V; Navarro Cabello MD; Martínez Vaquera S; Lopez-Andreu M; Aguera Morales ML; Rodriguez-Benot A; Aljama Garcia P
    Transplant Proc; 2015 Nov; 47(9):2618-21. PubMed ID: 26680052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients.
    Kang W; Sampaio MS; Huang E; Bunnapradist S
    Transplantation; 2017 Jun; 101(6):1303-1309. PubMed ID: 27336396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant Malignancies in Adult Renal and Hepatic Transplant Patients.
    Rahatli S; Altundag O; Ayvazoglu Soy E; Moray G; Haberal M
    Exp Clin Transplant; 2020 Aug; 18(4):470-473. PubMed ID: 30119617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancy in renal transplant recipients: a single-center experience in Thailand.
    Ruangkanchanasetr P; Lauhawatana B; Leawseng S; Kitpanich S; Lumpaopong A; Thirakhupt P
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S12-6. PubMed ID: 22934439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years.
    Zavos G; Moris D; Kostakis ID; Vernadakis S; Bokos J; Zavvos V; Lionaki S; Boletis J
    Exp Clin Transplant; 2015 Aug; 13(4):313-8. PubMed ID: 26295181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post kidney transplantation Kaposi's sarcoma: the experience of a Mediterranean North African center.
    Gorsane I; Bacha MM; Abderrahim E; Amri N; Hajri M; Ounissi M; Harzallah A; El Younsi F; Hedri H; Ben Abdallah T
    Clin Transplant; 2016 Apr; 30(4):372-9. PubMed ID: 26782303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer incidence and survival in kidney transplant patients.
    Navarro MD; López-Andréu M; Rodríguez-Benot A; Agüera ML; Del Castillo D; Aljama P
    Transplant Proc; 2008 Nov; 40(9):2936-40. PubMed ID: 19010153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients.
    Soler MJ; Puig JM; Mir M; Parrilla J; Pedro C; Salar A; Serrano S; Lloveras J
    Transplant Proc; 2003 Aug; 35(5):1709-13. PubMed ID: 12962767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long-Term Effect of Hepatitis C Virus on the Outcome of Live-Donor Kidney Transplant Recipients. A Retrospective Study.
    Denewar AA; Monem El-Hendy YA; Wafa EW; Ghorab AA; Sheashaa HA; Rashad RH; Nagib AM; Neamatallah AH; Abbas MH; Shokeir AA
    Exp Clin Transplant; 2015 Oct; 13(5):402-7. PubMed ID: 26450463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Hepatis C Virus-Related Immunologic Markers and Their Impact on Outcomes of Living-Donor Kidney Transplant Recipients.
    Denewar AA; Abbas MH; Sheashaa HA; Abdelaal I; El-Dahshan K; Matter YE; Refaie AF
    Exp Clin Transplant; 2019 Feb; 17(1):79-83. PubMed ID: 29957163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
    Kahan BD; Yakupoglu YK; Schoenberg L; Knight RJ; Katz SM; Lai D; Van Buren CT
    Transplantation; 2005 Sep; 80(6):749-58. PubMed ID: 16210961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.